Activity Report and Sales Note to Accompany Appendix 4C

Melbourne (Australia) – 30^th October 2020. Telix Pharmaceuticals provides its Activity Report and Appendix 4C for the quarter ending 30^th September 2020, and Q3 2020 sales update for its prostate cancer imaging product.

Highlights:

First formal interaction with the U.S. Food and Drug Administration (FDA) on the design of Phase III PROSTACT trial of TLX591 prostate cancer therapeutic product (7^th July)
Pre-investigational new drug (IND) meeting for TLX591 scheduled with the FDA for 24^th November to review final proposed PROSTACT trial design
New Drug Application (NDA) for TLX591-CDx prostate cancer imaging product lodged with the FDA (23^rd September)

To read the full ASX release please click here.

None of Telix’s product pipeline has received marketing authorization in any jurisdiction.